Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Given Average Recommendation of “Moderate Buy” by Brokerages

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) has received a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company.

A number of equities analysts recently issued reports on the stock. HC Wainwright initiated coverage on shares of Swedish Orphan Biovitrum in a research report on Wednesday, May 6th. They set a “buy” rating for the company. Pareto Securities lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Monday, June 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday. Zacks Research upgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, May 7th. Finally, Barclays reiterated an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd.

Swedish Orphan Biovitrum Stock Performance

Swedish Orphan Biovitrum stock opened at $49.03 on Thursday. The company has a quick ratio of 0.47, a current ratio of 0.70 and a debt-to-equity ratio of 0.19. The stock has a market cap of $17.45 billion, a PE ratio of 108.95 and a beta of 0.35. Swedish Orphan Biovitrum has a 12-month low of $28.93 and a 12-month high of $49.03. The business’s 50-day moving average price is $48.11 and its two-hundred day moving average price is $42.63.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last posted its earnings results on Tuesday, April 28th. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.07. Swedish Orphan Biovitrum had a net margin of 4.74% and a return on equity of 18.27%. The firm had revenue of $755.76 million during the quarter, compared to analysts’ expectations of $749.76 million. As a group, analysts expect that Swedish Orphan Biovitrum will post 1.94 earnings per share for the current fiscal year.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.